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Dermatofibrosarcoma protuberans (DFSP) is a
rare, low-grade malignant neoplasm that rarely
presents in children. It is locally aggressive with a
high rate of recurrence. We describe a boy who
presented with a slow-growing nodule that
was thought to be a pilar cyst. Histopathologic
examination provided the diagnosis of dermato-
fibrosarcoma protuberans myxoid variant, which is
one of the least common subtypes of DFSP.
CASE REPORT
A 13-year-old boy presented to the Pediatric
Dermatology Department with a 6-month history of
an asymptomatic, enlarging pink nodule on his
scalp. He could not recall any precipitating trauma
to the area, and he denied any pain, pruritus,
bleeding, or exudate. The lesion was not treated or
biopsied previously by his primary care team.
Physical examination found an otherwise healthy
boy with a 1.2-cm by 1.5-cm smooth, firm, fairly
mobile, pink nodule without a punctum on his scalp
and no regional lymphadenopathy (Fig 1).
An excisional biopsy of the nodule was
performed (Figs 2 and 3). Histopathologic examina-
tion found a poorly marginated, infiltrative dermal
spindle cell neoplasm that subtly infiltrated the
underlying subcutaneous fat in a honeycomb-like
fashion. Relatively monomorphic spindle-shaped
cells with tapering nuclei were present in a storiform
fashion with a myxoid matrix. Histiocytes and blood
vessels were also admixed within the lesion.
Immunohistochemical staining was positive for
CD34 and negative for S-100, factor XIIIa, and
smooth muscle actin (Fig 4). Fluorescence in situ
hybridization analysis found no evidence ofthe Department of Dermatology, University of California San
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The patient underwent Mohs micrographic
surgery (MMS) to achieve optimal clearance of the
margins; only 1 stage of MMS was required. The
final defect was 2.4 cm by 4.6 cm (Fig 5). After
confirmation of negative margins on formalin-fixed
tissue, final closure was performed by plastic surgery
under general anesthesia.DISCUSSION
DFSP is a rare cutaneous tumor that is locally
aggressive with the potential for hematogenous
metastasis.1-3 This tumor accounts for 1.0% to 1.8%
of all soft tissue sarcomas and less than 0.1% of all
malignancies.2,4 DFSP typically presents between the
ages of 20 and 50, but it has been reported in
children.4 Although some studies have found male
or female predominance, DFSP is generally thought
to affect both sexes equally.2-4 In addition, there
are several subtypes of DFSP: atrophic, classic,
fibrosarcomatous, granular cell, myxoid, pigmented
(Bednar tumor), and sclerosing.1,3,4 The myxoid
subtype, with which our patient presented, is one
of the least common variants.1,5
Clinically, DFSP often presents as an asymptom-
atic, indurated, violaceous plaque.3,4 It is fixed
to the skin and grows slowly for quite some
time before growing rapidly, adhering to deeperJAAD Case Reports 2015;1:129-31.
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Fig 3. Relatively monomorphic spindle-shaped cells
with tapering nuclei present in a storiform pattern
(Hematoxylin-eosin stain; original magnification, 310.)
Fig 1. DFSP. A 1.2-cm 3 1.5-cm smooth, firm, fairly
mobile, pink nodule without a punctum on the scalp of
a 13-year-old boy; no regional lymphadenopathy present.
Fig 2. A poorly marginated, infiltrative dermal spindle
cell neoplasm with a myxoid background. Note the
infiltration into the underlying subcutaneous fat in
a honeycomb-like fashion. (Hematoxylin-eosin stain;
original magnification, 32.)
Fig 4. Most spindle cells are CD341 (Immunohisto-
chemistry; original magnification, 32.)
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typically remains between 1 and 5 cm, although
some lesions may grow in excess of 20 cm.2-4
These lesions usually occur on the trunk, including
chest and shoulders, limbs, and head and neck, in
decreasing frequency.2-4 In children, acral areas are
most likely to be involved.3 It has been hypothesized
that prior trauma may trigger the development
of DFSP; however, only 10% to 20% are associated
with a definitive history of trauma.3,4 Our patient’s
presentation was less typical, as it consisted of a
single pink nodule on the scalp of a child.
The clinical differential diagnosis for DFSP on the
scalp of a child may include pilar cyst, dermoid cyst,
cylindroma, keloid, hypertrophic scar, melanoma,
and metastatic cancer.2,6 In general, the differential
diagnosis of DFSP has also been reported to include
mucinous cyst, myxoid mesenchymal neoplasms,
pyogenic granuloma, and synovial cyst.1,2,6
The diagnosis of DFSP is classically based on
histologic findings: spindle cells with a storiform
growth pattern invading the subcutaneous tissue
forming projections into the fat lobules.2-4,6 Thecentral areas of the lesion have greater cellularity,
whereas the periphery is more diffuse with a
honeycomb pattern.2 These features are typically
present, but less characteristic, in the myxoid
variant.5 Prominent features of myxoid DFSP include
myxoid stromal changes, multinodular growth, and
numerous branched or thickened vessels.6,7
Immunohistochemical analysis is typically positive
for CD34 (although 10%e20% may be negative),
vimentin, and CD99 but negative for factor XIIIa,
S-100, actin, and desmin.1,3
DFSP is thought to result from the reciprocal
translocation t(17;22)(q22;q13), leading to fusion of
the collagen, type I, alpha 1 and PDGFB genes
that cause aberrant activation of the PDGF receptor
and subsequent stimulation of cell growth.1,2,8
Fluorescence in situ hybridization or reverse
transcription polymerase chain reaction can isolate
this translocation and help identify the correspond-
ing collagen, type I, alpha 1 and PDGFB gene
mutations.3,8 In approximately 8% of DFSP cases,
however, these mutations are not detected.8
The treatment of choice for DFSP is complete
surgical resection.3,4 Because of the high recurrence
rate of these lesions, MMS is preferred overwide local
Fig 5. A 2.4-cm 3 4.6-cm final defect after MMS.
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performed on our patient, he did not require the use
of radiation therapy or imatinib mesylate (PDGFB
inhibitor), which have been used as adjuvant therapy
after surgery, primary therapy for unresectable
lesions, and treatment for metastatic disease.7,9
Because DFSP does not typically present in
children, it can be confused with other more
common lesions such as a pilar cyst. Therefore, it is
important that physicians consider the diagnosis of
DFSP in the pediatric population because it is a
malignant neoplasm that requires MMS for optimal
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